Company intelligence / Profile preview

LymeTek

Palm Beach Gardens, Florida, United States

Ownership: Private
Development stage: Other

Overview

LymeTek is a specialized biotechnology company focused on the development and commercialization of advanced diagnostic solutions for Lyme disease. The company's primary offering is a proprietary diagnostic test designed to improve the accuracy and speed of detecting Borrelia burgdorferi infections compared to traditional two-tier testing methods. By utilizing specific recombinant antigens, LymeTek aims to reduce the high rate of false negatives often associated with early-stage Lyme disease diagnosis. The company serves clinical laboratories and healthcare providers seeking more reliable tools for managing tick-borne illnesses.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic testELISA
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on LymeTek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LymeTek.

Explore the full profile